middle.news
Radiopharm clears FDA meeting hurdle as RAD101 moves towards Phase 3
8:40am on Monday 5th of October, 2026 AEDT
•
Biotechnology and pharmaceuticals
Read Story
Radiopharm clears FDA meeting hurdle as RAD101 moves towards Phase 3
8:40am on Monday 5th of October, 2026 AEDT
Key Points
Constructive FDA End-of-Phase 2 meeting completed for RAD101
Phase 2b data showed 93% concordance with MRI across evaluable lesions
Phase 3 readiness activities are already under way
Formal FDA meeting minutes expected within approximately 30 days
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE